The company’s market value has increased by approximately $3.3 billion over the past 5 days, bringing its current market capitalization to around $23 billion.

Biogen’s fair value estimate has inched up from $170.03 to $172.34, reflecting a slight improvement in the company’s intrinsic valuation. This update comes as analysts weigh recent progress in ...

Key Points Florida-based J. L. Bainbridge sold 119,376 shares of Biogen for an estimated $16.1 million in the third quarter. After the transaction, J. L. Bainbridge reported holding just 2,969 shares ...

Biogen has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock ...

Shares of Biogen Inc. jumped 10.09% to $154.22 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 0.34% to 6,711.20 and the ...

Jefferies began covering Biogen Inc. (NASDAQ:BIIB) on September 26 with a Buy rating and a price target of $190.

7 analysts have shared their evaluations of Biogen (NASDAQ: BIIB) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table provides a quick overview of ...

Discover why Biogen's MS drug growth, robust margins, and Alcyone acquisition signal a 'Strong Buy.' Click here to read my ...

Valued at a market cap of $22.1 billion, Biogen Inc. (BIIB) is a top biotechnology company. Headquartered in Cambridge, ...

This was the stock's sixth consecutive day of losses.

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the December 19th expiration. One of the key data points that goes into the price an option buyer is willing to pay, ...

Biogen Inc. closed 25.24% short of its 52-week high of $192.16, which the company reached on October 16th.